Skip to content

ResMed Inc.: net finite-lived intangible assets

ResMed net finite-lived intangible assets: $452.7 million at 2026-06-30, down 2.6% on the year. 17 values since 2010 from SEC filings. In original units.

All ResMed Inc. financial histories

At a glance

ResMed reported net finite-lived intangible assets of $452.7 million at 2026-06-30, down 2.6% from $464.9 million a year earlier. From 2010 to 2026 it grew at a compound 18.3% a year, from $30.9 million to $452.7 million. Across the last five reported years it ranged from $345.9 million (2022-06-30) to $552.3 million (2023-06-30). That was 5.0% of total assets ($8.97 billion) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Exact concept: us-gaap:FiniteLivedIntangibleAssetsNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-06-30 to 2026-06-30. The SEC response was captured on 2026-09-20.

Selected filing history

Net finite-lived intangible assets in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2026-06-30452,737,000USD2026-08-1310-K · 0000943819-26-000047 SEC
-2025-06-30464,861,000USD2026-08-1310-K · 0000943819-26-000047 SEC
-2024-06-30485,904,000USD2025-08-0810-K · 0000943819-25-000035 SEC
-2023-06-30552,341,000USD2024-08-0910-K · 0000943819-24-000013 SEC
-2022-06-30345,944,000USD2023-08-1110-K · 0000943819-23-000011 SEC
-2021-06-30392,582,000USD2022-08-1210-K · 0000943819-22-000010 SEC
-2020-06-30448,168,000USD2021-08-1710-K · 0000943819-21-000017 SEC
-2019-06-30521,950,000USD2020-08-1310-K · 0000943819-20-000013 SEC
-2018-06-30215,184,000USD2019-08-0810-K · 0000943819-19-000017 SEC
-2017-06-30261,800,000USD2018-08-1710-K · 0000943819-18-000013 SEC
-2016-06-30299,808,000USD2017-08-0410-K · 0001193125-17-248016 SEC
-2015-06-3047,142,000USD2016-08-0510-K · 0001193125-16-673607 SEC
-2014-06-3045,198,000USD2015-08-0710-K · 0001193125-15-281887 SEC
-2013-06-3049,639,000USD2014-08-0810-K · 0001193125-14-301852 SEC
-2012-06-3054,827,000USD2013-08-1310-K · 0001193125-13-331415 SEC
-2011-06-3047,911,000USD2012-08-1410-K · 0001193125-12-353206 SEC
-2010-06-3030,925,000USD2011-08-1710-K · 0001193125-11-224622 SEC

Related ResMed Inc. histories

All 63 ResMed histories

Inspect the source

Entity
ResMed Inc. / CIK 0000943819
Captured
SEC response SHA-256
e34475f86d51c5a2a7c037bcf07aaa6b9a48ac8827a8fbde2be0b6c1cbc3ac74

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000943819.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))